PerspectiveCancer Immunotherapy

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

See allHide authors and affiliations

Science Translational Medicine  28 Mar 2012:
Vol. 4, Issue 127, pp. 127ps8
DOI: 10.1126/scitranslmed.3003634

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

View Full Text